Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis

Nat Rev Clin Oncol. 2023 Apr 11:1-2. doi: 10.1038/s41571-023-00762-1. Online ahead of print.


Immune-checkpoint-inhibitor-associated myocarditis has a high fatality rate, warranting the development of more-effective treatment strategies. Herein, we discuss a recent report of a series of patients who were managed using a novel approach that involved personalized abatacept dosing, ruxolitinib and close respiratory monitoring, which was associated with low mortality.

PMID:37041273 | PMC:PMC10088759 | DOI:10.1038/s41571-023-00762-1


Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

Generated by Feedzy